Raymond E. Cabillot Sells 1,000 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,000 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the completion of the transaction, the director now directly owns 299,695 shares in the company, valued at approximately $14,984,750. This trade represents a 0.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Pro-Dex Stock Down 0.3 %

Pro-Dex stock opened at $48.92 on Friday. The firm has a market capitalization of $159.53 million, a price-to-earnings ratio of 24.34 and a beta of 0.68. The company’s 50 day simple moving average is $39.78 and its 200 day simple moving average is $39.11. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. Pro-Dex, Inc. has a fifty-two week low of $16.84 and a fifty-two week high of $59.60.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, sell-side analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Pro-Dex from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th.

Institutional Investors Weigh In On Pro-Dex

Several large investors have recently modified their holdings of PDEX. Northern Trust Corp lifted its holdings in shares of Pro-Dex by 14.1% during the 4th quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock valued at $1,672,000 after purchasing an additional 4,426 shares in the last quarter. Geode Capital Management LLC lifted its stake in Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after buying an additional 529 shares during the period. EAM Investors LLC acquired a new stake in shares of Pro-Dex during the fourth quarter worth $1,047,000. Finally, O Shaughnessy Asset Management LLC acquired a new stake in shares of Pro-Dex during the fourth quarter worth $995,000. 15.28% of the stock is currently owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.